Omega-3 Fatty Acids and Longevity: EPA, DHA, and the Pro-Resolving Science

Omega-3 Fatty Acids & Longevity: EPA, DHA, and the Pro-Resolving Science That Changes Everything

Table of Contents

• What Are Omega-3s — and Why the Type Matters
• How EPA and DHA Work at the Cellular Level
• Specialized Pro-Resolving Mediators — The Resolution Revolution
• The VITAL and REDUCE-IT Trials — What the Evidence Shows
• Brain Health, Cognitive Protection, and Eye Function
• Sources, Dosing, and the Omega-3 Index
• Clinical Connection — Omega-3 and Foot & Ankle Health
• Frequently Asked Questions

Of all the nutritional interventions with genuine longevity evidence, omega-3 fatty acids occupy a unique position: they are not merely anti-inflammatory in the conventional sense of blocking inflammatory pathways, but actively pro-resolving — they generate a class of signaling molecules that switch off NF-κB, clear cellular debris, promote tissue repair, and restore homeostasis after inflammatory challenge. This distinction matters profoundly: blocking inflammation with NSAIDs or corticosteroids can impair healing; resolving it with omega-3-derived mediators facilitates it. For a functional medicine podiatrist managing conditions from diabetic foot ulcers to plantar fasciitis to peripheral arterial disease, omega-3 fatty acids are not a wellness supplement — they are a clinical tool with mechanisms as well-characterized as many pharmaceuticals.

The clinical trial evidence has matured substantially over the past decade. After years of contradictory results from trials using low-dose fish oil (1g/day), the VITAL and REDUCE-IT trials clarified the dose-response and context-dependency of omega-3 cardiovascular benefits — with results strong enough to shift prescribing recommendations in cardiology. Meanwhile, the neuroscience of DHA’s role in brain structure and function has illuminated why omega-3 insufficiency is a modifiable risk factor for cognitive decline — and why the average American’s omega-3 status (Omega-3 Index 4–5%) is so far below the cardioprotective threshold (≥8%) that most people are chronically under-resourced in one of biology’s most critical anti-inflammatory and neuroprotective fatty acids.

What Are Omega-3s — and Why the Type Matters

Omega-3 fatty acids are a family of polyunsaturated fatty acids characterized by the first double bond position counting from the methyl (omega) end of the carbon chain. Three omega-3s are nutritionally relevant:

• ALA (alpha-linolenic acid, 18:3n-3): Found in plant sources (flaxseed, chia seeds, walnuts, hemp seeds). ALA is an essential fatty acid — the body cannot synthesize it — but it has minimal direct biological activity. Its value lies in its conversion to EPA and DHA, which is highly inefficient: studies consistently show only 5–15% of dietary ALA converts to EPA, and less than 1–4% converts to DHA in healthy adults. Factors further limiting conversion: high dietary omega-6 linoleic acid (competes for the same elongase/desaturase enzymes), insulin resistance, and aging-related enzyme activity decline.
• EPA (eicosapentaenoic acid, 20:5n-3): Found in fatty fish (salmon, mackerel, sardines, herring, anchovies) and algae. EPA is the primary substrate for anti-inflammatory eicosanoids (PGE3, TXA3) and for the resolution mediators E-series resolvins (RvE1, RvE2, RvE3). EPA is highly active as an anti-inflammatory and pro-resolving agent and is the primary mediator of omega-3’s triglyceride-lowering effect.
• DHA (docosahexaenoic acid, 22:6n-3): Found in fatty fish and algae. DHA is the dominant structural fatty acid of the brain and retina — comprising approximately 30–40% of phospholipid fatty acids in neuronal membranes and 50–60% of total fatty acids in photoreceptor outer segments. DHA is the primary substrate for D-series resolvins (RvD1, RvD2), protectin D1 (neuroprotectin D1), and maresins — resolution mediators with potent neuroprotective effects.

How EPA and DHA Work at the Cellular Level

EPA and DHA exert their biological effects through three primary mechanisms that operate at different levels of cellular biology.

1. Cell Membrane Incorporation and Fluidity

EPA and DHA are incorporated into the phospholipid bilayer of all cell membranes, where their highly unsaturated structure (5 and 6 double bonds, respectively) prevents the tight packing that saturated and monounsaturated fatty acids create. This increases membrane fluidity — particularly critical for neurons (where synaptic membrane flexibility determines receptor clustering and signal transduction efficiency), immune cells (where membrane fluidity affects cytokine receptor signaling and phagocytic capacity), and cardiovascular cells (where red blood cell deformability — essential for navigating capillaries — depends on membrane composition). The omega-3/omega-6 ratio in cell membranes is a direct function of dietary intake: a diet with a high omega-3:omega-6 ratio produces membranes rich in EPA/DHA; a typical Western diet with a 1:15–20 omega-3:omega-6 ratio produces membranes rich in arachidonic acid (omega-6), shifting the cellular environment toward pro-inflammatory eicosanoid production.

2. Competitive Substrate for Inflammatory Enzyme Pathways

When cell membranes are damaged or activated (by cytokines, physical stress, or oxidants), phospholipase A2 liberates fatty acids from membrane phospholipids to serve as substrates for prostaglandin and leukotriene synthesis. When the liberated fatty acid is arachidonic acid (omega-6), COX enzymes produce pro-inflammatory PGE2 and TXA2; LOX enzymes produce pro-inflammatory LTB4. When EPA is present in significant membrane quantities, it competes with arachidonic acid for the same COX and LOX enzymes — producing instead PGE3 (much less inflammatory than PGE2) and TXA3 (much less vasoconstricting than TXA2). This competitive displacement is one mechanism by which a high omega-3:omega-6 ratio lowers the body’s inflammatory tone — without blocking the enzymes (as NSAIDs do) but by shifting the substrate balance away from pro-inflammatory products.

3. Direct Transcriptional Effects — PPAR-alpha and NF-κB

EPA and DHA are direct ligands for PPAR-alpha (peroxisome proliferator-activated receptor alpha) — a nuclear receptor that drives expression of fatty acid oxidation genes and directly suppresses NF-κB transcriptional activity. By activating PPAR-alpha, omega-3s reduce expression of COX-2, iNOS, IL-6, IL-1β, and TNF-α at the level of gene transcription — a downstream anti-inflammatory effect independent of the membrane and eicosanoid mechanisms. This PPAR-alpha activation also explains part of omega-3’s triglyceride-lowering effect (PPAR-alpha drives fatty acid beta-oxidation in the liver, reducing VLDL-TG secretion) and its protective effects on macrophage inflammatory activation in atherosclerotic plaques.

The Resolution Revolution: Specialized Pro-Resolving Mediators

For decades, we described omega-3s as “anti-inflammatory” — a technically correct but fundamentally incomplete picture. The real story is more sophisticated, and it changes everything about why these fats matter for longevity.

EPA and DHA are not simply passive inhibitors of arachidonic acid metabolism. They are the molecular precursors to an entirely separate class of signaling molecules: Specialized Pro-Resolving Mediators (SPMs). These lipid mediators — resolvins, protectins (also called neuroprotectins), and maresins — don’t suppress inflammation. They actively resolve it. The distinction is crucial.

Resolvins: Switching Off the Inflammatory Program

Charles Serhan’s lab at Harvard Medical School pioneered SPM research beginning in the late 1990s, and the findings are still reverberating through clinical medicine. EPA generates E-series resolvins (RvE1, RvE2, RvE3), while DHA generates D-series resolvins (RvD1, RvD2, RvD3) and their aspirin-triggered counterparts (AT-RvD1, AT-RvD3). These molecules act on specific G-protein coupled receptors — ERV1/ChemR23 for RvE1, GPR32 and ALX/FPR2 for RvD1 — to orchestrate tissue cleanup after an inflammatory event.

What RvE1 and RvD1 do is remarkable: they halt neutrophil recruitment (stopping new damage), promote macrophage phagocytosis of cellular debris (clearing the battlefield), and stimulate the apoptosis of spent neutrophils so they don’t spill their toxic contents into surrounding tissue. This is active resolution — a genetically programmed shutdown sequence that requires specific molecular keys. Without adequate EPA and DHA to generate SPMs, that shutdown sequence either never fully fires or fires with significant delay. The result is smoldering, unresolved inflammation that slowly accumulates organ damage over decades.

Protectins and Maresins: Tissue Repair and Neural Protection

DHA also generates protectin D1 (PD1), sometimes called neuroprotectin D1 (NPD1) in the central nervous system, where it plays a specific protective role. NPD1 suppresses apoptosis in neurons and retinal pigment epithelial cells during oxidative stress, activates anti-apoptotic Bcl-2 family proteins, and inhibits the pro-apoptotic cascade. A 2013 study in Scientific Reports demonstrated that NPD1 production in retinal cells drops precipitously under conditions of aging-related oxidative stress — and that restoring DHA substrate availability rescues NPD1 synthesis and prevents cell death.

Maresins (Macrophage mediators in resolving inflammation), synthesized by macrophages from DHA via 12-LOX, add a third resolution pathway. Maresin-1 (MaR1) has demonstrated potent capacity to reduce pain signaling in inflammatory models (10,000-fold more potent than EPA/DHA on a molar basis in some neuroinflammation assays), enhance tissue regeneration through planarian stem cell models, and reduce NLRP3 inflammasome activation — directly targeting the same pathway that drives SASP-related aging pathology.

What VITAL and REDUCE-IT Actually Proved

For years, omega-3 cardiovascular trials produced conflicting results, and the field was mired in debate. The landmark VITAL and REDUCE-IT trials settled the core questions — while simultaneously raising important nuances about dose, population, and form.

The VITAL Trial: 1 Gram, 25,871 Adults, 5.3 Years

The VITAL trial (Vitamin D and Omega-3 Trial), published by JoAnn Manson and colleagues in The New England Journal of Medicine in 2019, enrolled 25,871 U.S. adults (men ≥50, women ≥55) with no prior cardiovascular disease. Participants received 1 gram per day of marine omega-3s (840 mg EPA+DHA combined) versus placebo for a median of 5.3 years. Primary endpoints were major cardiovascular events (MACE: heart attack, stroke, CV death) and invasive cancer.

The headline result: omega-3 supplementation reduced myocardial infarction by 28% (HR 0.72, 95% CI 0.59–0.90, p=0.003) — with the benefit concentrated in participants with low dietary fish intake, where MI reduction reached 40%. Fatal MI was reduced by 50% in the omega-3 group. Total MACE showed a 15% reduction trend (HR 0.92, CI 0.80–1.06) that did not meet statistical significance for the composite endpoint, but the component analysis for MI was unambiguous. Critically, the fish-eaters showed less benefit — suggesting that the trial was largely measuring the effect of correcting deficiency, not supraphysiologic dosing.

REDUCE-IT: The High-Dose EPA Story

Published by Deepak Bhatt and colleagues in NEJM in November 2018, REDUCE-IT enrolled 8,179 statin-treated patients with elevated triglycerides (135–499 mg/dL) and either established cardiovascular disease or diabetes plus other risk factors. Participants received 4 grams per day of icosapentaenoic acid ethyl ester (IPE, Vascepa) — EPA only, no DHA — versus mineral oil placebo.

The results were striking: a 25% relative risk reduction in the primary composite endpoint (HR 0.75, 95% CI 0.68–0.83, p<0.001). CV death was reduced by 20%, MI by 31%, stroke by 28%. The number needed to treat to prevent one primary endpoint event was 21 over 4.9 years — among the best NNTs ever recorded for a cardiovascular intervention in a statin-treated cohort. This raised an important mechanistic question: is the effect dose-dependent, EPA-specific, or was the mineral oil placebo itself pro-inflammatory? Subsequent analyses suggest all three factors play a role, and a complementary trial (STRENGTH, using corn oil control) with a different omega-3 formulation showed less benefit — but REDUCE-IT's clinical signal remains robust and FDA-approved (Vascepa for CV risk reduction).

What These Trials Mean for Longevity Practice

Synthesizing both trials: a modest daily dose (1g) corrects deficiency and meaningfully reduces MI risk in people not eating fish regularly. A high pharmacologic dose (4g EPA) produces landmark cardiovascular event reduction in high-risk, statin-treated patients with hypertriglyceridemia. For the broad population seeking longevity optimization, the practical takeaway is that an Omega-3 Index ≥8% — achievable with 2–3g/day combined EPA+DHA in triglyceride (not ethyl ester) form — represents the target that carries the most consistent mortality benefit across epidemiologic and interventional data.

Omega-3s, Brain Aging, and Retinal Health

DHA is the most abundant polyunsaturated fatty acid in the brain, comprising 30–40% of the total fatty acid content of neuronal membrane phospholipids and reaching 50–60% in the rod outer segments of the retina. These aren’t coincidental concentrations — they reflect millions of years of evolutionary selection for DHA’s unique biophysical properties: exceptional membrane fluidity even at low temperatures, enabling faster signal transduction in neurons, and unparalleled capacity to generate NPD1 and other neuroprotective SPMs.

Cognitive Decline and Dementia Risk

Prospective epidemiological data from the PREDIMED (Prevención con Dieta Mediterránea) trial — 447 cognitively healthy participants at high cardiovascular risk, median age 74.6 — found that assignment to a Mediterranean diet supplemented with mixed nuts (rich in ALA) was associated with significantly better performance on the Mini-Mental State Examination and the Clock Drawing Test at 6.5 years compared to control diet. While PREDIMED was not an isolated omega-3 trial, its omega-3-enriched olive oil and nut components provide the most rigorous randomized evidence for dietary pattern-level neuroprotection.

At the molecular level, DHA supports cognitive function through multiple mechanisms: it is the precursor to NPD1, which protects hippocampal and cortical neurons from amyloid-beta-induced apoptosis; it maintains the fluidity of neuronal membranes required for proper NMDA receptor function and synaptic vesicle fusion; and it regulates brain-derived neurotrophic factor (BDNF) expression through PPAR-gamma activation in hippocampal tissue. A 2016 review in Ageing Research Reviews compiled data showing that lower plasma DHA is consistently associated with smaller hippocampal volume on MRI — the structural biomarker most tightly linked to Alzheimer’s disease risk.

Retinal DHA and Age-Related Macular Degeneration

The retinal concentration of DHA is physiologically extraordinary — the photoreceptor outer segment membrane is the most DHA-dense biological structure in the human body, enabling the rapid conformational changes in rhodopsin required for phototransduction. Age-related macular degeneration (AMD), the leading cause of blindness in adults over 50, involves progressive loss of retinal pigment epithelial (RPE) cells and photoreceptors — exactly the cell types protected by NPD1 synthesized from DHA.

The AREDS2 (Age-Related Eye Disease Study 2) trial, which enrolled 4,203 participants with intermediate-to-advanced AMD, examined the addition of omega-3s (650 mg DHA + 350 mg EPA daily) to the standard AREDS antioxidant formulation. While AREDS2 did not show additional benefit from omega-3 supplementation over the standard formulation in an already-supplement-enriched cohort, observational data consistently show that individuals in the highest quartile of dietary omega-3 intake have a 38–68% lower risk of developing advanced AMD compared to the lowest quartile (SanGiovanni et al., Archives of Ophthalmology, 2008, n=2,924). The retina’s dependence on DHA availability is not in question; the debate is whether supplementation on top of an already omega-3-replete state provides incremental benefit.

Sources, Dosing, and the Omega-3 Index: A Practical Guide

Understanding the mechanism is one thing. Translating it into a practical protocol requires knowing the difference between an adequate dietary omega-3 status and actual tissue sufficiency — and those two things are not the same.

The Omega-3 Index: Your Red Blood Cell Report Card

William Harris and Clemens von Schacky introduced the Omega-3 Index in 2004 as a clinical biomarker: the percentage of EPA+DHA in red blood cell membrane phospholipids, expressed as a percentage of total fatty acids. Because red blood cells turn over every 90–120 days, the Omega-3 Index reflects a 3-month average of tissue EPA+DHA status — far more informative than a fasting plasma level, which fluctuates with recent intake.

Their meta-analysis, published in Preventive Medicine in 2004, established the risk categories: an Omega-3 Index ≥8% is associated with the lowest cardiovascular risk, while an index of 4–8% represents intermediate risk, and <4% carries the highest risk. The average American has an Omega-3 Index of 4–5% — firmly in the intermediate-risk zone. Most Japanese adults eating traditional diets test at 8–12%. The clinical goal for longevity optimization is ≥8%, with many longevity physicians targeting 10%.

Food Sources vs. Supplements

Fatty cold-water fish are the most EPA/DHA-dense foods available. A 3.5-oz (100g) serving of wild Atlantic salmon provides approximately 2,150 mg combined EPA+DHA; sardines in oil provide about 1,480 mg; mackerel provides 2,670 mg; and albacore tuna canned in water provides approximately 730 mg. Two to three servings of fatty fish per week — the standard recommendation — provides roughly 500–1,000 mg EPA+DHA daily, which is sufficient to maintain but typically not enough to raise a low Omega-3 Index into the ≥8% target range.

For supplementation, the key variables are form, dose, and oxidation status. Triglyceride-form fish oil (re-esterified) has demonstrated 26–73% higher bioavailability compared to ethyl ester form in direct comparative trials. Phospholipid-bound omega-3s (krill oil) show similar or superior absorption to triglyceride form, particularly for DHA. For most people targeting an Omega-3 Index ≥8%, a practical starting dose is 2–3 grams per day of combined EPA+DHA in triglyceride form. Retesting the Omega-3 Index at 3–4 months allows for dose titration. For those with documented cardiovascular risk and elevated triglycerides, the REDUCE-IT protocol (4g/day of prescription EPA-only icosapentaenoic acid) is FDA-approved and clinically validated.

Supplement quality matters substantially. Fish oil oxidizes readily — rancid fish oil may actually cause harm through oxidized lipid byproducts. Third-party testing (IFOS, GOED standards) for peroxide values ≤5 mEq/kg and anisidine values ≤20 is the minimum standard. Capsules that smell strongly fishy or taste harsh are likely oxidized and should be discarded. Refrigerating open bottles slows oxidation significantly.

Clinical Connection: Omega-3s in Lower Extremity and Vascular Health

In my practice at Balance Foot & Ankle, I see the downstream consequences of omega-3 deficiency every day — though they rarely present as “omega-3 deficiency.” They present as peripheral arterial disease, chronic wound complications, painful neuropathy, and persistent soft tissue inflammation that resists standard treatment. Understanding the omega-3 biology reframes each of these presentations.

Peripheral Arterial Disease: Anti-Platelet and Anti-Atherogenic Effects

EPA competes directly with arachidonic acid for platelet COX-1, producing thromboxane A3 (TxA3) — a weak platelet aggregator — instead of the potent TxA2 generated from AA. This shifts the balance toward less sticky platelets without the bleeding risk of NSAIDs. EPA also upregulates endothelial nitric oxide synthase (eNOS) expression and reduces expression of VCAM-1 and ICAM-1 — the adhesion molecules that allow monocytes to embed in arterial walls and initiate atherosclerotic plaques. In PAD patients, where both atherogenesis and microvascular insufficiency converge in the lower limbs, an Omega-3 Index ≥8% represents a modifiable risk factor that most vascular workups ignore entirely.

Diabetic Peripheral Neuropathy: Membrane Composition and Resolution

DPN is not simply a consequence of hyperglycemia-induced axonal damage — it’s also a failure of neural membrane maintenance and a failure of neuroinflammation resolution. Peripheral nerve myelin sheaths are rich in DHA-containing phosphatidylserine and phosphatidylethanolamine. When chronic hyperglycemia drives glycation of structural proteins and oxidative stress in Schwann cells, DHA availability becomes rate-limiting for membrane repair. Additionally, the painful component of DPN — driven by upregulated TRPV1 and Nav1.7 in sensitized C-fibers — involves persistently unresolved neuroinflammation that SPMs, particularly RvE1 acting on ChemR23 in dorsal root ganglion neurons, directly suppress. In a 2018 study in Molecular Pain, resolvin E1 injected into the paw of streptozotocin-diabetic mice reduced mechanical allodynia by 63% within 2 hours — a response magnitude comparable to gabapentin at equimolar doses, without sedation or tolerance.

Chronic Wound Healing: The SPM-Mediated Resolution Phase

Wound healing has four overlapping phases: hemostasis, inflammation, proliferation, and remodeling. The transition from inflammation to proliferation — the single most common failure point in chronic diabetic foot wounds — requires active resolution mediated by SPMs. Macrophage phenotype switching from M1 (pro-inflammatory, TNF-α/IL-1β secreting) to M2 (anti-inflammatory, TGF-β/VEGF secreting) is partially driven by maresin-1 acting on LGR6 receptors. Fibroblast migration into the wound bed, the critical step in granulation tissue formation, is enhanced by RvD1 through its effects on leukocyte clearance and extracellular matrix remodeling. In patients with chronic non-healing ulcers, testing the Omega-3 Index has become part of my nutritional assessment — not because omega-3 supplementation alone heals wounds, but because a 4% Omega-3 Index means the patient lacks the raw materials to generate the resolution signals the wound needs to close.

Frequently Asked Questions

The Bottom Line

Sources

1. Manson JE, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med. 2019;380(1):23-32. PMID 30415637
2. Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapentaenoic Acid for Hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11-22. PMID 30415628
3. Harris WS, von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med. 2004;39(1):212-20. PMID 15208005
4. Serhan CN, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196(8):1025-37. PMID 12391014
5. Bazan NG, et al. Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer’s, and other neurodegenerative diseases. Annu Rev Nutr. 2011;31:321-51. PMID 21756132
6. Martínez-Lapiscina EH, et al. Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. J Neurol Neurosurg Psychiatry. 2013;84(12):1318-25. PMID 23670794

Related Articles

• Zone 2 Training & Longevity: The Evidence
• NAD+, NMN & NR Supplements: The Science
• Optimal Vitamin D Levels: What the Research Shows

Dive Deeper into Longevity

• Telomeres and Longevity
• Blue Zones and Longevity
• Optimal Protein Intake for Longevity
• Zone 2 Training & Longevity